Please login to the form below

Not currently logged in
Email:
Password:

Repatha

This page shows the latest Repatha news and features for those working in and with pharma, biotech and healthcare.

Novartis picks up inclisiran after completion of MedCo acquisition

Novartis picks up inclisiran after completion of MedCo acquisition

This dosing schedule means that MedCo’s drug could pose a major challenge to established drugs in the class, including Amgen’s Repatha (evolocumab) and Sanofi/Regeneron’s Praluent (alirocumab). ... Repatha and Praluent are dosed more frequently –

Latest news

More from news
Approximately 32 fully matching, plus 44 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    Repatha from Amgen was the first in the class to be approved in Japan in January, although it will likely only be months before Sanofi's rival Praluent will join it

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics